🆕 GSK licenses novel ADC for advanced prostate cancer

GSK inked a deal to globally develop and commercialize Syndivia's preclinical ADC for mCRPC, in a pact worth over $350M.

Why It Matters To Oncology

▪ mCRPC remains challenging with limited targeted options; ADCs offer a precision approach.

▪ Syndivia's asset, using GeminiMab tech, showed strong antitumor effects and safety in preclinical studies.

The Financials

▪ Deal includes undisclosed upfront payment, milestones up to 268M ($357.2M), plus tiered royalties.

What They're Saying

▪ GSK's Hesham Abdullah: ADC complements GSKs tumor-targeted portfolio, including B7-H3 ADC GSK'227.

What's Next

▪ GSK to advance the ADC into clinical development; watch for updates on safety and efficacy in humans.

▪ Further integration with GSKs growing ADC pipeline expected.